v3.22.2.2
Segment Information
 3 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
The Company evaluates the performance of its segments based on segment earnings before other (expense) income, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization (“Segment EBITDA”).
Segment EBITDA is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA (a) because Segment EBITDA is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Company’s presentation of Segment EBITDA may not be comparable to similarly titled measures used by other companies.
The following tables include Segment EBITDA for each of the Company's current reportable segments during the three months ended September 30, 2022 and 2021:
(Dollars in millions)Three Months Ended  
September 30,
20222021
Segment EBITDA reconciled to net earnings:
Biologics$113 $167 
Pharma and Consumer Health108 99 
Sub-Total$221 $266 
Reconciling items to net earnings
Unallocated costs (1)
(87)(56)
Depreciation and amortization(99)(81)
Interest expense, net(32)(26)
Income tax expense(3)(10)
Net earnings$— $93 
(1) Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:                                                        
(Dollars in millions)Three Months Ended  
September 30,
20222021
Impairment charges and gain/loss on sale of assets$2 $(3)
Stock-based compensation(19)(21)
Restructuring and other special items (a)
(9)(8)
Gain on sale of subsidiary (b)
— 1 
Other expense, net (c)
(25)(9)
Unallocated corporate costs, net(36)(16)
Total unallocated costs$(87)$(56)
(a)    Restructuring and other special items during the three months ended September 30, 2022 include (i) transaction costs associated with the Metrics Contracts Services (“Metrics”) acquisition and (ii) warehouse exit costs for a product the Company no longer manufactures in its respiratory and specialty platform.
Restructuring and other special items during the three months ended September 30, 2021 include (i) transaction and integration costs associated with the Delphi Genetics SA, Hepatic Cell Therapy Support SA, and RheinCell Therapeutics GmbH acquisitions (ii) transaction costs associated with the Bettera Holdings, LLC acquisition, and (iii) restructuring costs associated with the closure of the Company's facility in Bolton, U.K.
(b)    Gain on sale of subsidiary for the three months ended September 30, 2021 was due to the sale of the facility in Woodstock, Illinois and the associated business.
(c)    Other expense, net during the three months ended September 30, 2022 includes foreign currency remeasurement losses/gains.
Other expense, net during the three months ended September 30, 2021 includes financing charges related to the Company’s Incremental Term B-3 Loans and foreign currency remeasurement losses/gains.
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements.
(Dollars in millions)September 30,
2022		June 30,
2022
Assets:
Biologics$5,651 $5,770 
Pharma and Consumer Health4,262 4,355 
Corporate and eliminations292 382 
Total assets$10,205 $10,507